medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2015, Número 2

<< Anterior Siguiente >>

Dermatología Cosmética, Médica y Quirúrgica 2015; 13 (2)


Dermatofibrosarcoma protuberans: una revisión

González MEM, Lacy NRM, Boeta ÁL, Vega MME

Idioma: Español
Referencias bibliográficas: 40
Paginas: 149-158
Archivo PDF: 250.29 Kb.


RESUMEN

El dermatofibrosarcoma protuberans (dfsp) es un tumor cutáneo fibrohistiocítico, de lento crecimiento pero con comportamiento infiltrante y altas tasas de recidiva local. A pesar de que clínicamente puede sospecharse, su diagnóstico es sobre todo histopatológico y se debe complementar con inmunohistoquímica. El tratamiento de elección es quirúrgico, se recomienda cirugía micrográfica de Mohs y su pronóstico depende de diversos factores, como la edad del paciente, su topografía, tamaño mayor a 5 cm, recurrencia y un elevado índice mitótico (más de 10 mitosis por campo de 10x). La principal vía de diseminación es hematógena con metástasis pulmonares entre 2 y 4% de los casos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Criscione, V.D. y Weinstock, M.A., “Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002”, J Am Acad Dermatol, 2007, 56: 968-973.

  2. Llombart, B., Serra-Guillén, C., Monteagudo, C., López Guerrero, J.A. y Sanmartín, O., “Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management”, Seminars in Diagnostic Pathology, 2013, 30, 13-28.

  3. Gloster, H.M., Jr., “Dermatofibrosarcoma protuberans”, J Am Acad Dermatol, 1996, 35: 355-374.

  4. Serra-Guillén, C., Llombart, B. y Sanmartín, O., “Dermatofibrosarcoma protuberans”, Actas Dermosifiliogr, 2012, 103 (9): 762-777.

  5. Edelweiss, M. y Malpica, A., “Dermatofibrosarcoma protuberans of the vulva: a clinico pathologic and immunohistochemical study of 13 cases”, Am J Surg Pathol, 2010, 34: 393.

  6. Gooskens, S.L., Oranje, A.P., Adrichem, A.N.A., Waard-Van, F.B., Hollander, J.C., Van de Ven, C.P. et al., “Imatinib mesylate for children with dermatofibrosarcoma protuberans”, Pediatr Blood Cancer, 2010, 55: 369-373.

  7. Tsai, Y.-J., Pao-Yuan, Lin, Khong-Yik, Chew y Yuan-Cheng, Chiang, “Dermatofibrosarcoma protuberans in children and adolescents: Clinical presentation, histology, treatment, and review of the literature” Journal of Plastic, Reconstructive & Aesthetic Surgery, 2014, http://dx.doi. org/ 10.1016/j.bjps.2014.05.031.

  8. Llombart, B., Sanmartín, O. y López Guerrero, J.A., “Dermatofibrosarcoma protuberans en la infancia”, Piel, 2006, 21: 435-441.

  9. Sanmartín, O., Llombart, B., López Guerrero, J.A. et al., “Dermatofibrosarcoma protuberans”, Actas Dermosifiliogr, 2007, 98: 77-87.

  10. Lautier, R., Wolff, H.H. y Jones, R.E., “An immunohistochemical study of dermatofibrosarcoma protuberans supports its fibroblasticcharacter and contradicts neuroectodermalor histiocytic components”, Am J Dermatopathol, 1990, 12: 25-30.

  11. Allan, A.E., Tsou, H.C., Harrington, A., Stasko, T., Lee, X., Si, S.P. et al., “Clonalorigin of dermatofibrosarcoma protuberans”, J InvestDermatol, 1993, 100: 99-102.

  12. Bowne, W.B., Antonescu, C.R., Leung, D.H. et al., “Dermatofibrosarcoma protuberans: A clinico pathologic analysis of patients treated and followed at a single institution”, Cancer, 2000, 88: 2711.

  13. The esmo (European Sarcoma Network Working Group), “Softt issue and visceral sarcomas: esmo Clinical Practice Guidelines for diagnosis, treatment and follow-up”, Annals of Oncology, 2012, 23 (Supplement 7): 92-99.

  14. Zelger, B., Sidoroff, A., Stanzl, U., Fritsch, P.O., Ofner, D., Zelger, B. et al., “Deep penetrating dermatofibroma versus dermatofibrosarcoma protuberans. A clinico pathologic comparison”, Am J Surg Pathol, 1994, 18: 677-686.

  15. Weedon, D., Weedon’s skin pathology, 3ª ed., Elsevier, 2010, cap. 34: 833- 835.

  16. Abenoza, P., Lillemoe T: cd34 and factor xiiia in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans”, Am J Dermatopathol, 1993, 15: 429-434.

  17. West, R.B., Harvell, J., Linn, S.C., Liu, C.L., Prapong, W., Hernández-Boussard, T. et al., “Apo D in softt tissue tumors: a novel marker for dermatofibrosarcoma protuberans”, Am J Surg Pathol, 2004, 28: 1063-1069.

  18. Abbott, J.J., Oliveira, A.M. y Nascimento, A.G., “The prognostic significance of fibrosarcomatous transformation in dermatofibrosarcoma protuberans”, Am J Surg Pathol, 2006, 30: 436-443.

  19. Ahmed, A.A., Ostlie, D., Fraser, J., Newell, B. y Cooley, L., “Dermatofibrosarcoma protuberans in the breast of a 2-year-old girl”, Ann Diag Pathol, 2010, 14: 279-283.

  20. Pedeutour, F., Simon, M.P., Minoletti, F. et al., “Translocation t(17; 22) (q22;q13) in dermatofibrosarcoma protuberans: a new tumor associated chromosomere arrangement”, Cytogenet Cell Genet, 1996, 72: 171-174.

  21. Sang Yun, Ha et al., dfsp rearrangement in dermatofibrosarcoma protuberans: correlation with clinicopathologic characteristics and clinical implications”, Human Pathology, 2013, 44: 1300-1309.

  22. Bianchini, L., Maire, G., Guillot, B. et al., “Complex t(5;8) involving the cspg2 and ptk2b genes in a case of dermatofibrosarcoma protuberans without the col1a1-pdgfb fusion”, Virchows Arch, 2008, 452: 689-696.

  23. Llombart, B., Monteagudo, C., Sanmartín, O., López-Guerrero, J.A., Serra-Guillén, C., Poveda, A., Jorda, E. et al., “Dermatofibrosarcoma protuberans: A clinico pathological, immunohistochemical, genetic (col1a1-pdgfb), and therapeutic study of low-grade versus high-grade (fibrosarcomatous) tumors”, J Am Acad Dermatol, 2011, 65: 564-575.

  24. Serra-Guillén, C., Sanmartín, O., Llombart, B. et al., “Correlation between preoperative magnetic resonance imaging and surgical margins with modified Mohs for dermatofibrosarcoma protuberans”, Dermatol Surg, 2011, 37: 1638-1645.

  25. National Comprehensive Cancer Network, “Dermatofibromasarcoma protuberans”, 2014, http://www.nccn.org/professionals/physician_ gls/pdf/dfsp.pdf.

  26. Khatri, V.P., Galante, J.M., Bold, R.J., Schneider, P.D., Ramsamooj, R., Goodnight, Jr, J.E., “Dermatofibrosarcoma protuberans: reappraisal of wide local excision and impact of inadequate initial treatment”, Ann Surg Oncol, 2003, 10: 1118-1122.

  27. Bowne, W.B., Antonescu, C.R., Leung, D.H. et al., “Dermatofibrosarcoma protuberans: a clinico pathologic analysis of patients treated and followed at a single institution”, Cancer, 2000, 88: 2711-2720.

  28. Rutgers, E.J., Kroon, B.B., Albus-Lutter, C.E. y Gortzak, E., “Dermatofibrosarcoma protuberans: treatment and prognosis”, Eur J Surg Oncol, 1992, 18: 241-248.

  29. Loghdey, S., Varma, S., Rajpara, S., Al-Rawi, H., Perks, G. y Perkins, W., “Mohs micrographic surgery for dermatofibrosarcoma protuberans (pdgf): A single-centre series of 76 patients treated by frozen-section Mohs micrographic surgery with a review of the literature”, Journal of Plastic, Reconstructive & Aesthetic Surgery, 2014, http://dx.doi. org/10.1016/j.bjps.2014.05.021.

  30. Paradisi, A., Abeni, D., Rusciani, A., Cigna, E., Wolter, M., Scuderi, N. et al., Dermatofibrosarcoma protuberans: wide local excision vs. Mohs micrographicsurgery”, Cancer Treat Rev, 2008, 34: 728-736.

  31. Buck, D., Kim, J., Alam, M., Rawlani, W., Johnson, S., Connor, C., Dumanian, G. y Wayne, J., “Multidisciplinary approach to the management of dermatofibrosarcoma protuberans”, J Am Acad Dermatol, 2012, 67: 861-866.

  32. Dagan R, Morris CG, Zlotecki RA, et al., “Radiotherapy in the treat-ment of dermatofibrosarcoma protuberans”, Am J Clin Oncol, 2005,28:537.539

  33. Castle, K., Guadagnolo, B., Tsai, C., Feig, B. y Zagars, G., “Dermatofibrosarcoma protuberans: Long-term outcomes of 53 Patients Treated with Conservative Surgery and Radiation Therapy”, Int J Radiation Oncol Biol Phys, 2013, 86: 585-590.

  34. Lindner NJ, Scarborough MT, Powel GJ, et al.,”Revisión surgery in dermatofibrosarcoma protuberans of the trunk and extremities”,Eur J Surg Oncol, 1999; 25:392

  35. Van der Graaf, W. y Gelderblom, H., “New Systemic Therapy Options for Advanced Sarcomas”, Current Treatment Options in Oncology, 2012, 13: 306–317.

  36. Lemm, D., Mugge, L.O., Mentzel, T. y Höffken, K., “Current treatment options in dermatofibrosarcoma protuberans”, J Cancer Res Clin Oncol, 2009, 135: 653-655.

  37. McArthur, G.A., “Molecular targeting of dermatofibrosarcoma protuberans: a new approach to a surgical disease”, J Natl Compr Canc Netw, 2007, 5: 557-562.

  38. Rutkowski, P., Van Glabbeke, M., Rankin, C.J. et al., Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase ii clinical trials”, J Clin Oncol, 2010, 28: 1772–1779.

  39. Pretel-Irazabal, M., Tuneu-Valls, A. y Ormaechea, N., “Efectos adversos cutáneos del imatinib (inhibidor de la tirosíncinasa)”, Actas Dermosifiliogr, 2013, http://dx.doi.org/10.1016/j.ad.2013.01.009.

  40. http://economia.gob.mx/transparencia/transparenciafocalizada/precios_ max_medicamentos_patente_2014_0111.




2020     |     www.medigraphic.com